GlobeNewswire 11/12/2021 Sio Gene Therapies Announces Corporate Updates and Fiscal Second Quarter 2021 Financial Results

GlobeNewswire 11/11/2021 Sio Gene Therapies Announces Successful Manufacture of Three GMP Batches of AXO-Lenti-PD Gene Therap...

GlobeNewswire 10/19/2021 Oxford Biomedica Announces that Boehringer Ingelheim has Exercised Option Relating to a Novel Gene T...

GlobeNewswire 9/22/2021 Oxford Biomedica announces strategic investment by Serum Life Sciences Ltd

GlobeNewswire 9/22/2021 Oxford Biomedica Plc INTERIM RESULTS FOR THE SIX MONTHS ENDED 30 JUNE 2021

GlobeNewswire 8/12/2021 Sio Gene Therapies Announces Corporate Updates and Fiscal First Quarter 2021 Financial Results

GlobeNewswire 7/15/2021 Oxford Biomedica Appoints Dr. Michael Hayden as Non-Executive Director

GlobeNewswire 6/9/2021 Sio Gene Therapies Announces Fiscal Year 2020 Year-End Financial Results and Expected Fiscal Year 20...

GlobeNewswire 6/8/2021 Pacific Biosciences Welcomes Neil Ward to Its Leadership Team as Vice President and General Manager ...

GlobeNewswire 5/18/2021 Oxford Biomedica upgrades financial guidance for supply agreement with AstraZeneca for manufacture o...

GlobeNewswire 4/15/2021 Oxford Biomedica plc Preliminary results for the year ended 31 December 2020

GlobeNewswire 4/6/2021 Oxford Biomedica signs a new three year Development & Supply Agreement with Boehringer Ingelheim for...

GlobeNewswire 2/9/2021 Sio Gene Therapies Announces Financial Results for Third Fiscal Quarter Ended December 31, 2020

GlobeNewswire 2/3/2021 Oxford Biomedica plc: Board Changes

GlobeNewswire 12/30/2020 Oxford Biomedica notes AstraZeneca’s COVID-19 vaccine has been authorised for emergency supply in th...

GlobeNewswire 11/23/2020 Oxford Biomedica notes AstraZeneca’s AZD1222 met primary efficacy endpoint in preventing COVID-19

GlobeNewswire 11/23/2020 Oxford Biomedica Appoints Dr. Sam Rasty as Non-Executive Director

GlobeNewswire 11/13/2020 Sio Gene Therapies Announces Corporate Updates and Financial Results for Second Fiscal Quarter Ended...

GlobeNewswire 10/29/2020 Axovant Gene Therapies to Present AXO-Lenti-PD Program Update During Virtual Parkinson’s Disease R&D...

GlobeNewswire 10/6/2020 Oxford Biomedica notes Axovant’s positive six-month follow-up from second cohort of SUNRISE-PD Phase...

GlobeNewswire 9/17/2020 OXFORD BIOMEDICA PLC INTERIM RESULTS FOR THE SIX MONTHS ENDED 30 JUNE 2020

GlobeNewswire 9/1/2020 Oxford Biomedica Signs Supply Agreement with AstraZeneca to Expand Manufacturing Support of COVID-19...

GlobeNewswire 8/11/2020 Axovant Announces Corporate Updates and Financial Results for First Fiscal Quarter Ended June 30, 20...

GlobeNewswire 8/3/2020 Oxford Biomedica Signs Development, Manufacture & License Agreement with Beam Therapeutics Inc., for...